

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/221765485>

Chemical Constituents from the Aerial Parts of *Aster koraiensis* with Protein Glycation and Aldose Reductase Inhibitory Activities

ARTICLE in JOURNAL OF NATURAL PRODUCTS · FEBRUARY 2012

Impact Factor: 3.8 · DOI: 10.1021/np200646e · Source: PubMed

CITATION

1

READS

30

5 AUTHORS, INCLUDING:



Jun Lee

Korea Institute of Oriental Medicine, Daejeon, ...

52 PUBLICATIONS 474 CITATIONS

SEE PROFILE



Byong Won Lee

48 PUBLICATIONS 582 CITATIONS

SEE PROFILE



Joo-Hwan Kim

Gachon University


76 PUBLICATIONS 564 CITATIONS

SEE PROFILE

Chemical Constituents from the Aerial Parts of *Aster koraiensis* with Protein Glycation and Aldose Reductase Inhibitory ActivitiesJun Lee,[†] Yun Mi Lee,[†] Byong Won Lee,[‡] Joo-Hwan Kim,[§] and Jin Sook Kim^{*,†}[†]Diabetic Complications Research Center, Division of Traditional Korean Medicine (TKM) Integrated Research, Korea Institute of Oriental Medicine (KIOM), Daejeon 305-811, Republic of Korea[‡]Division of Legume & Oil Crop Research, Department of Functional Crop, National Institute of Crop Science, RDA, Milyang 627-803, Republic of Korea[§]Department of Life Science, Kyungwon University, Seongnam 461-701, Republic of Korea

S Supporting Information

ABSTRACT: Two new eudesmane-type sesquiterpene glucosides, 9 β -O-(*E*-*p*-hydroxycinnamoyl)-1 β ,6 β -dihydroxy-*trans*-eudesm-3-en-6-O- β -D-glucopyranoside (**1**) and 9 α -O-(*E*-*p*-hydroxycinnamoyl)-1 α ,6 α -11-trihydroxy-*trans*-eudesm-3-en-6-O- β -D-glucopyranoside (**2**), were isolated by the activity-guided fractionation of an EtOAc-soluble fraction from the aerial parts of *Aster koraiensis*. A new dihydrobenzofuran glucoside, (2*R*,3*S*)-6-acetyl-2-[1-O-(β -D-glucopyranosyl)-2-propenyl]-5-hydroxy-3-methoxy-2,3-dihydrobenzofuran (**3**), was also isolated, in addition to 15 known compounds. The structures of **1**–**3** were determined by spectroscopic data interpretation. All of the isolates were evaluated for in vitro inhibitory activity against the formation of advanced glycation end-products and rat lens aldose reductase.



Aster koraiensis (Nakai) Kitamura (syn. *Gymnaster koraiensis*, Compositae), an endemic Korean species, is distributed in the southern and central parts of the Korean peninsula and Jeju Island. It is grown widely as a decorative plant for its beautiful and long-lasting flowers, and its young leaves and stems are used as a food source in Korea. This plant has been used to remedy pertussis, chronic bronchitis, and pneumonia in traditional Korean medicine.^{1–4} Previous research on this plant has reported that it contains several types of polyacetylenes,^{5–7} benzofurans,⁸ and sesquiterpenoids^{9,10} associated with biological activities such as cytotoxicity,⁵ modulation of antinuclear factor in activated T cells,⁷ and hepatoprotection.¹¹

As part of an ongoing project directed toward discovering new preventive agents against diabetic complications using medicinal herbs, it has been reported previously that an ethanol extract from the aerial parts of *A. koraiensis* showed a preventive effect against diabetic nephropathy.¹² No other studies on diabetes or diabetic complications by this herb have been reported. In the present investigation, three new compounds (**1**–**3**) and 15 known compounds were isolated from this plant. All of the isolates were evaluated in vitro for their inhibitory activity against the formation of advanced glycation end-products (AGEs) and rat lens aldose reductase (RLAR; alditol/NADP⁺ oxidoreductase, E.C.1.1.1.21). Previous studies have demonstrated that AGE accumulation and AR play an important role in the pathogenesis of diabetic complications,

such as cataracts, retinopathy, neuropathy, and nephropathy.^{13–18} Thus, the elucidation of AGE and AR inhibitors may be a potential therapeutic strategy for the prevention and treatment of diabetic complications.^{19,20}

Compound **1** was obtained as a white, amorphous solid with the molecular formula C₃₀H₄₂O₁₀, which was deduced from the HRESIMS peak at *m/z* 561.2708 [*M* – H][–] (calcd for C₃₀H₄₁O₁₀, 561.2705). In addition to the signals for a glucopyranose unit, the ¹³C NMR data showed signals for 28 carbons, comprising a carbonyl group (δ 168.8), four methyl groups (δ 21.9, 21.8, 21.8, 11.8), two sp³ methylenes (δ 29.6, 29.1), three sp³ methines (δ 52.2, 51.4, 29.1), three oxygenated methines (δ 81.3, 80.3, 75.9), five sp² methines (δ 146.8, 131.4, 120.2, 117.0, 116.3), and four quaternary carbons (δ 161.4, 136.2, 127.3, 42.2). The ¹H NMR spectrum showed signals for *trans*- α,β -unsaturated protons [δ 7.63 (1H, d, *J* = 16.0 Hz), 6.34 (1H, d, *J* = 16.0 Hz)], two aromatic protons [δ 7.48 (2H, d, *J* = 8.5 Hz), 6.81 (2H, d, *J* = 8.5 Hz)], and a *E*-*p*-hydroxycinnamoyl group. On the basis of the ¹H, ¹³C, and 2D-NMR data (¹H–¹H COSY, HMQC, and HMBC) and a comparison of NMR data with eudesmane sesquiterpenes,¹⁰ **1** was found to be similar to 1,6-dihydroxyeudesm-3-ene, except for the glucopyranosyl and *E*-*p*-hydroxycinnamoyl groups. The β -form of D-glucose was assigned using the coupling constant of the anomeric proton

Received: August 3, 2011

Published: January 20, 2012

(δ 4.39, J = 8.0 Hz).²¹ The HMBC correlations of H-1'' [δ 4.39 (1H, d, J = 8.0 Hz)] with C-6 (δ 75.9) and of H-9 [δ 4.98 (1H, dd, J = 10.5 and 6.0 Hz)] with C-9' (δ 168.8) indicate that the D-glucopyranose and *E-p*-hydroxycinnamoyl groups are linked to C-6 and C-9, respectively. The relative configurations of the hydroxy groups at C-1, C-6, and C-9 were all β , based on the NOESY correlations for H-1 with H-5/H-9, H-7 with H-5/H-6/H-9, and H-9 with H-5 (Figure 1), whereas no NOESY




Figure 1. Key NOESY (\leftrightarrow , 1 and 2) and HMBC (\rightarrow , 2 and 3) correlations.

correlation was observed with H-14. Thus, compound 1 was assigned as 9 β -O-(*E-p*-hydroxycinnamoyl)-1 β ,6 β -dihydroxy-*trans*-eudesm-3-en-6-O- β -D-glucopyranoside.

Compound 2 was obtained as a white, amorphous solid with the molecular formula $C_{30}H_{42}O_{11}$ from the HRESIMS peak at m/z 601.2616 [$M + Na$]⁺ (calcd for $C_{30}H_{42}O_{11}Na$, 601.2619). The NMR spectra for 2 were similar to compound 1 except for an additional quaternary oxygenated carbon signal in the ^{13}C NMR spectrum being observed. Compound 2 exhibited signals for three oxygenated methines (δ 79.9, 80.2, 80.1) and an additional quaternary oxygenated carbon (δ 72.7). The position of the quaternary oxygenated carbon at δ 72.7 was established as C-11 because the coupling pattern [δ 1.37 (3H, s) and 1.21 (3H, s)] in the 1H NMR spectrum was different from that for 1 (Table 1). Further, the C-11 (δ 72.7) signal correlated with H-6 and H-8 in the HMBC experiment (Figure 1). The relative configuration was confirmed from the NOESY data (Figure 1), which showed correlations between H-1 and H-9, H-7 and H-5, and H-6 and H-12. Therefore, compound 2 was established as 9 α -O-(*E-p*-hydroxycinnamoyl)-1 α ,6 α -11-trihydroxy-*trans*-eudesm-3-en-6-O- β -D-glucopyranoside.

Compound 3 was obtained as a yellowish solid with the molecular formula $C_{20}H_{26}O_{10}$ observed from the HRESIMS at m/z 449.1418 [$M + Na$]⁺ (calcd for $C_{20}H_{26}O_{10}Na$, 449.1418). The 1H and ^{13}C NMR data showed signals for a carbonyl group, a sp^2 methylene, a sp^3 oxygenated methylene, two oxygenated methines, two aromatic methines, a methyl, a methoxy group, and five sp^2 quaternary carbons, in addition to a glucopyranose moiety. A carbonyl, four double bonds, and a glucopyranose were evident from the ^{13}C NMR data. On the basis of the 1H , ^{13}C , and 2D-NMR (1H - 1H COSY, HMQC, and HMBC), the two degrees of unsaturation remaining were attributed to a benzofuran ring system with a $-C(CH_2)-CH_2-OH$ unit and one acetyl group. In the HMBC experiment on 3,

Table 1. 1H and ^{13}C NMR Data (CD_3OD) for Compounds 1 and 2


position	1		2	
	δ_H (J in Hz)	δ_C , mult.	δ_H (J in Hz)	δ_C , mult.
1	4.89 m ^a	81.3, CH	4.91 dd (10.0, 6.0)	79.9, CH
2 α	2.25 m	29.6, CH ₂	2.24 m	29.4, CH ₂
2 β	2.09 m			
3	5.30 brs	120.2, CH	5.33 brs	120.9, CH
4		136.2, C		135.9, C
5	2.11 brs	52.2, CH	2.12 brs	52.4, CH
6	4.47 brs	75.9, CH	4.50 brs	80.2, CH
7	1.18 m	51.4, CH	1.56 m	51.3, CH
8 α	1.93 m	29.1, CH ₂	2.19 m	26.0, CH ₂
8 β			1.90 m	
9	4.98 dd (10.5, 6.0)	80.3, CH	5.05 dd (11.5, 4.5)	80.1, CH
10		42.2, C		42.3, C
11	1.98 m	29.1, CH		72.7, C
12	1.02 d (6.5)	21.8, CH ₃	1.37 s	29.1, CH ₃
13	0.92 d (6.5)	21.8, CH ₃	1.21 s	29.4, CH ₃
14	1.37 s	11.8, CH ₃	1.39 s	12.1, CH ₃
15	1.87 s	21.9, CH ₃	1.77 s	22.3, CH ₃
1'		127.3, C		127.2, C
2'	7.48 d (8.5)	131.4, CH	7.48 d (8.5)	131.5, CH
3'	6.81 d (8.5)	117.0, CH	6.80 d (8.5)	117.1, CH
4'		161.4, C		161.8, C
5'	6.81 d (8.5)	117.0, CH	6.80 d (8.5)	117.1, CH
6'	7.48 d (8.5)	131.4, CH	7.48 d (8.5)	131.5, CH
7'	7.63 d (16.0)	146.8, CH	7.62 d (16.0)	146.8, CH
8'	6.34 d (16.0)	116.3, CH	6.33 d (16.0)	116.0, CH
9'		168.8, C		168.9, C
1''	4.39 d (8.0)	104.4, CH	4.40 d (8.0)	105.4, CH
2''	3.16 brt (8.0)	76.2, CH	3.18 dd (9.0, 7.5)	75.8, CH
3''	3.32 m	78.5, CH	3.38 m	78.2, CH
4''	3.31 m	72.0, CH	3.33 m	72.3, CH
5''	3.21 m	77.5, CH	3.23 m	77.3, CH
6''	3.83 dd (11.5, 2.5)	63.3, CH ₂	3.80 dd (12.0, 3.0)	63.6, CH ₂
	3.69 dd (11.5, 5.5)		3.67 dd (11.5, 5.5)	

^aSignal partially overlapped with the solvent signal.

the following long-range correlations were observed: C-13 (δ 206.1) with H-7 (δ 7.35) and H-14 (δ 2.62) as well as C-12 (δ 70.3) with H-2 (δ 5.21) (Figure 1). These results suggested that the acetyl group and the $-C(CH_2)-CH_2-OH$ are attached to the C-6 and C-2 positions, respectively. The β -form of D-glucose was assigned from the coupling constant of the anomeric proton (δ 4.26, J = 7.5 Hz).²² The HMBC correlation of C-12 (δ 70.3) with H-1' (δ 4.26) demonstrated that the D-glucopyranose group is attached to C-12. The H-2 and H-3 protons were determined as *trans* positioned by the $J_{2,3}$ coupling constant of 2.5 Hz. The absolute configuration of the C-2 position was determined to be *R* on the basis of the negative sign for optical rotation.²³ Consequently, compound 3 was identified as (2*R*,3*S*)-6-acetyl-2-[1-O-(β -D-glucopyranosyl)-2-propenyl]-5-hydroxy-3-methoxy-2,3-dihydrobenzofuran.

The 15 known compounds were identified as 3,5-di-O-caffeoylquinic acid (4),²⁴ 4,5-di-O-caffeoylquinic acid (5),²⁵ 5-O-caffeoylquinic acid (6),²⁶ isorhamnetin-3-O- β -D-glucopyranoside (7),²⁷ isoquercitrin (8),²⁸ quercetin-3-O- α -L-arabinopyranoside (9),²⁹ isorhamnetin-3-O- β -D-rutinoside (10),³⁰ larycitrin-3-O- α -L-rhamnopyranoside (11),³¹ kaempferol-3-O- β -D-rutinoside (12),³² gymnasterkoreayne E,⁵ gymnasterkoreaside A,⁶ 8*E*-decaene-4,6-diyn-1-O- β -D-glucopyranoside,³³ daucosterol,³⁴

α -spinasterol,³⁵ and eugenyl-4-*O*- β -D-glucopyranoside.³⁶ Compounds 4–12 were isolated from this plant for the first time.



All isolates were evaluated *in vitro* for inhibitory activity against the formation of AGEs and RLAR (Table 2). In the

Table 2. Inhibitory Effects of Compounds 4–12 from the Aerial Parts of *A. koraiensis* against AGE Formation and RLAR

compound	inhibitory effect (IC ₅₀ value; μ M) ^a	
	AGE formation ^b	RLAR
4	6.6 \pm 0.04	0.30 \pm 0.05
5	6.4 \pm 0.12	2.3 \pm 0.47
6	>50	0.95 \pm 0.28
7	44.4 \pm 0.61	9.3 \pm 1.96
8	9.2 \pm 0.27	4.4 \pm 0.28
9	9.0 \pm 0.21	0.32 \pm 0.04
10	>50	12.1 \pm 2.37
11	8.2 \pm 0.08	7.4 \pm 0.93
12	>50	11.3 \pm 2.05
AG ^c	965.9 \pm 26.9	
EP ^c		0.067 \pm 0.009

^aThe inhibitory effect is presented as the mean \pm SD from triplicate experiments. The IC₅₀ values were calculated from the dose inhibition curve. ^bAfter incubating for 14 days, the fluorescent reaction products were assayed on a spectrofluorometric detector. ^cAminoguanidine (AG) and epalrestat (EP) were used as positive controls. Compounds 1–3, gymnasterkoreayne E, gymnasterkoreasides A, 8*E*-decaene-4,6-diyn-1-*O*- β -D-glucopyranoside, daucosterol, α -spinasterol, and eugenyl-4-*O*- β -D-glucopyranoside were inactive in both the AGE (IC₅₀ > 50 μ M) and RLAR (IC₅₀ > 30 μ M) assays.

AGE assay, compounds 4, 5, and 8–10 showed inhibitory activities with IC₅₀ values 6.6, 6.4, 9.2, 9.0, and 8.2 μ M, respectively. In the RLAR assay, compound 4 showed the most potent inhibitory activity, with an IC₅₀ value of 0.30 μ M, which was followed by compounds 9 (IC₅₀ = 0.32 μ M) and 6 (IC₅₀ = 0.95 μ M) (Table 2). These results indicated that the above two major groups, the quinic acids and flavonoids, are the main contributors to the activities of this edible herb. Further biological studies on this plant and its constituents are necessary to develop the potential use in the prevention and treatment of diabetic complications and other related diseases.

EXPERIMENTAL SECTION

General Experimental Procedures. The optical rotations were obtained using a JASCO P-2000 digital polarimeter. The UV spectra were measured on a Varian Cary 300 spectrophotometer, and the IR spectra were recorded on a JASCO FTIR-4100 spectrophotometer. The LRESIMS and HRESIMS results were measured on a hybrid ion-trap time-of-flight mass spectrometer (Shimadzu LCMS-IT-TOF) that was equipped with an ESI source (ESI-IT-TOFMS). The NMR

experiments were conducted on either a Bruker DRX-300 or a Bruker Advance 500 FT-NMR, with tetramethylsilane (TMS) as the internal standard. TLC analysis was performed on silica gel 60 F₂₅₄ (Merck) and RP-18 F_{254S} (Merck) plates. Silica gel (230–400 mesh, Merck), reversed-phase silica gel (YMC, ODS-A, 12 nm, S-150 μ m), Sephadex LH-20 (Amersham Pharmacia Biotech), and Diaion HP-20 (Supelco) were used for column chromatography (CC). The preparative MPLC system (Yamazen YFLC AI-580, Osaka, Japan) was equipped with a solvent delivery pump (pump 580), a variable UV wavelength detector (prep UV-10V), and a fraction collector (FR360). Ultra Pack glass columns (C-18 ODS prepacked; size C: 37 \times 300 mm, size B: 26 \times 300 mm; 50 μ m, 120 Å, Yamazen) and Hi-Flash 2 L disposable columns (silica gel prepacked; 26 \times 150 mm; 40 μ m, 45 g, Yamazen) were used for separation. Prep AI software was used for data collection.

Plant Material. The aerial parts of *Aster koraiensis* were collected in Euidang-myun, Gongju city, Chungcheongnam-do, Republic of Korea, in August 2007, and identified by one of the authors (J.-H.K.). A voucher specimen (no. KIOM-ASKO2) was deposited at the Herbarium of the Diabetic Complications Research Center, Division of Traditional Korean Medicine (TKM) Integrated Research, Korea Institute of Oriental Medicine, Republic of Korea.

Extraction and Isolation. The dried and ground plant material (2.5 kg) was extracted with EtOH (3 \times 20 L) by maceration at room temperature for 3 days. The extracts were combined and concentrated *in vacuo* at 40 °C to produce a dried extract (303 g). This EtOH extract was suspended in water and partitioned with solvents of increasing polarity, to generate *n*-hexane- (37.5 g), EtOAc- (34.4 g), *n*-BuOH- (81.3 g), and water-soluble extracts (149 g). The active EtOAc extract (34.4 g) was separated by chromatography using a silica gel column (CHCl₃–EtOAc, 20:1 to 2:1, CHCl₃–MeOH, 3:1 to 1:1, CHCl₃–MeOH–water, 7:4:1), to generate 10 fractions (F01–F10). α -Spinasterol (white needle, 50 mg) and daucosterol (white needle, 128 mg) were recrystallized from F03 (878 mg) and F07 (2.26 g), respectively. Fraction F04 (364 mg) was separated by chromatography using a silica gel column (CHCl₃–EtOAc, 20:1 to 1:1), and an ODS-A reversed-phase column (water–MeOH, 2:8 to 0:10) was used to generate gymnasterkoreayne E (brown oil, 20 mg). Fraction F08 (11.5 g) was separated by chromatography, using a silica gel column eluted with a CH₂Cl₂–MeOH gradient mixture (20:1 to 1:1) to generate seven subfractions (F0801–F0807). Further separation of F0806 (793 mg) was performed by MPLC using an Ultra Pack C column [MeOH–water, 3:7 (60 min), 4:6 (30 min), 5:5 (200 min), 10:0 (60 min); flow rate: 12 mL/min] to generate gymnasterkoreaside A (brown oil, 50 mg) and 7 (yellow powder, 20 mg). Subfraction F0804 (2.23 g) was subjected to Sephadex LH-20 column chromatography (MeOH 100%) and MPLC [MeOH–water, 3:7 (60 min), 4:6 (100 min), 5:5 (150 min); Ultra Pack B column; flow rate: 5 mL/min] to generate 8*E*-decaene-4,6-diyn-1-*O*- β -D-glucopyranoside (amorphous solid, 19 mg), eugenyl-4-*O*- β -D-glucopyranoside (light yellow powder, 18 mg), and 3 (yellow powder, 3 mg). Chromatographic separation of fraction F09 (8.56 g) was performed using MPLC [MeOH–water, 1:9 (60 min), 2:8 (90 min), 3:7 (60 min), 4:6 (70 min), 10:0 (80 min); Ultra Pack C column; flow rate: 12 mL/min] to produce 16 subfractions (F0901–F0916). Compound 4 (white powder, 170 mg) was purified by precipitation in MeOH from subfraction F0904. Compounds 8 (yellow powder, 29 mg), 9 (yellow powder, 9 mg), 10 (yellow powder, 15 mg), 11 (yellow powder, 8 mg), 5 (white powder, 18 mg), and 12 (yellow powder, 7 mg) were separated from subfractions F0908 (276 mg) and F0909 (348 mg), respectively, by MPLC [CHCl₃–MeOH–water, 8:2:0.2 (100 min), 7:3:0.5 (100 min), MeOH 100% (100 min); Hi-Flash 2 L column; flow rate: 3 mL/min]. Subfractions F0911 (220 mg) and F0913 (258 mg) were subjected to MPLC [CHCl₃–MeOH–water, 8:2:0.2 (150 min), 7:3:0.5 (150 min); Hi-Flash 2 L column; flow rate: 3 mL/min] to generate 1 (white, amorphous solid, 32 mg) and 2 (white, amorphous solid, 10 mg), respectively. Fraction F10 (1.40 g) was fractionated by MPLC using an Ultra Pack C column [MeOH–water, 1:9 (70 min), 2.5:7.5 (30 min), 4:6 (60 min), 10:0 (80 min); flow rate: 10 mL/min], which yielded seven subfractions (F1001–F1007). Further chromatographic separation of subfraction F1002 (85 mg) was also performed by MPLC [MeOH–water, 0.5:9.5 (250 min); Ultra Pack B column; flow rate: 3 mL/min], and

the subfraction was then purified by Sephadex LH-20 column chromatography to generate **6** (white powder, 10 mg).

9 β -O-(E-p-Hydroxycinnamoyl)-1 β ,6 β -dihydroxy-trans-eudesm-3-en-6-O- β -D-glucopyranoside (1): amorphous powder; $[\alpha]_D^{20}$ +42.0 (c 0.05, MeOH); UV (MeOH) λ_{\max} (log ϵ) 313 (4.68) nm; ^1H (CD₃OD, 500 MHz) and ^{13}C (CD₃OD, 75 MHz) NMR data, see Table 1; HRESIMS m/z 561.2708 $[\text{M} - \text{H}]^-$ (calcd for C₃₀H₄₁O₁₀, 561.2705).

9 α -O-(E-p-Hydroxycinnamoyl)-1 α ,6 α -11-trihydroxy-trans-eudesm-3-en-6-O- β -D-glucopyranoside (2): amorphous powder; $[\alpha]_D^{20}$ +78.0 (c 0.05, MeOH); UV (MeOH) λ_{\max} (log ϵ) 312 (4.49) nm; ^1H (CD₃OD, 500 MHz) and ^{13}C (CD₃OD, 150 MHz) NMR data, see Table 1; HRESIMS m/z 601.2616 $[\text{M} + \text{Na}]^+$ (calcd for C₃₀H₄₂O₁₁Na, 601.2619).

(2R,3S)-6-Acetyl-2-[1-O-(β -D-glucopyranosyl)-2-propenyl]-5-hydroxy-3-methoxy-2,3-dihydrobenzofuran (3): yellow powder; $[\alpha]_D^{20}$ -49.0 (c 0.05, MeOH); UV (MeOH) λ_{\max} (log ϵ) 259 (4.36), 368 (4.08) nm; ^1H NMR (CD₃OD, 500 MHz) δ 7.35 (1H, s, H-7), 7.01 (1H, s, H-4), 5.28 (1H, s, H-11), 5.22 (1H, s, H-11), 5.21 (1H, overlapped, H-2), 5.05 (1H, d, J = 2.5 Hz, H-3), 4.47 (1H, d, J = 12.5 Hz, H-12), 4.26 (1H, d, J = 7.5 Hz, H-1'), 4.22 (1H, d, J = 12.5 Hz, H-12), 3.87 (1H, dd, J = 2.0, 12.0 Hz, H-6'), 3.66 (1H, dd, J = 5.5, 12.0 Hz, H-6'), 3.47 (3H, s, 3-OMe), 3.33 (1H, m, H-3'), 3.27 (1H, m, H-4'), 3.25 (1H, m, H-5'), 3.20 (1H, dd, J = 8.0, 9.0 Hz, H-2'), 2.62 (3H, s, H-14); ^{13}C NMR (CD₃OD, 150 MHz) δ 206.1 (C, C-13), 158.4 (C, C-5), 144.1 (C, C-10), 136.4 (C, C-9), 121.7 (C, C-6), 116.9 (CH, C-4), 115.3 (CH₂, C-11), 111.0 (CH, C-7), 103.9 (CH, C-1'), 89.3 (CH, C-2), 85.6 (CH, C-3), 78.3 (CH, C-3'), 78.2 (CH, C-5'), 75.2 (CH, C-2'), 71.9 (CH, C-4'), 70.3 (CH₂, C-12), 63.0 (CH₂, C-6'), 56.7 (3-OCH₃), 27.4 (CH₃, C-14); HRESIMS m/z 449.1418 $[\text{M} + \text{Na}]^+$ (calcd for C₂₀H₂₆O₁₀Na, 449.1418).

Determination of AGE Formation. Inhibitory activity against the formation of advanced glycation end-products for the isolates was evaluated according to an established method.³⁷

RLAR Inhibition Assay. All of the experiments were performed in accordance with the U.S. National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. The crude RLAR was prepared from the eyes of 8-week-old male Sprague–Dawley rats (Orient Co., Seongnam, Korea).^{38,39} The isolates were assayed according to a method described previously with slight modifications.⁴⁰

■ ASSOCIATED CONTENT

Supporting Information

^1H and ^{13}C NMR spectra for the new compounds **1–3** are available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: +82-42-868-9465. Fax: +82-42-868-9471. E-mail: jskim@kiom.re.kr.

■ ACKNOWLEDGMENTS

This research was supported by a grant [K10040] from the Korea Institute of Oriental Medicine. The NMR and MS experiments were performed by the Korea Basic Science Institute (KBSI).

■ REFERENCES

- (1) Kwon, J.; Kang, S.; Shen, S.; Park, C. *Mycobiology* **2001**, *29*, 58–60.
- (2) Lee, J. K.; Han, B. K. *J. Kor. Trad. Landscape Gard. Soc.* **1995**, *13*, 39–48.
- (3) Ahn, D. K. *Illustrated Book of Korean Medicinal Herbs*; Kyo-Hak Publishing: Seoul, 1998.
- (4) Ko, J. Y.; Lee, K. K. *RDA J. Agric. Sci.* **1996**, *38*, 627–632.
- (5) Jung, H. J.; Min, B. S.; Park, J. Y.; Kim, Y. H.; Lee, H. K.; Bae, K. H. *J. Nat. Prod.* **2002**, *65*, 897–901.

(6) Park, J. Y.; Min, B. S.; Jung, H. J.; Kim, Y. H.; Lee, H. K.; Bae, K. H. *Chem. Pharm. Bull.* **2002**, *50*, 685–687.

(7) Dat, N. T.; Cai, X. Fu.; Shen, Q.; Lee, I. S.; Lee, E. J.; Park, Y. K.; Bae, K. H.; Kim, Y. H. *Chem. Pharm. Bull.* **2005**, *53*, 1194–1196.

(8) Dat, N. T.; Kiem, P. V.; Cai, X. F.; Shen, Q.; Bae, K. H.; Kim, Y. H. *Arch. Pharm. Res.* **2004**, *27*, 1106–1108.

(9) Lee, I. K.; Kim, K. H.; Ryu, S. Y.; Lee, K. R. *Heterocycles* **2009**, *78*, 2827–2835.

(10) Lee, I. K.; Kim, K. H.; Ryu, S. Y.; Choi, S. U.; Lee, K. R. *Bull. Korean Chem. Soc.* **2010**, *31*, 227–229.

(11) Lee, S. B.; Kang, K.; Oidovsambuu, S.; Jho, E. H.; Yun, J. H.; Yoo, J.; Lee, E.; Pan, C.; Lee, J. K.; Jung, S. H.; Nho, C. W. *Food Chem. Toxicol.* **2010**, *48*, 3035–3041.

(12) Sohn, E.; Kim, J.; Kim, C.; Kim, Y. S.; Jang, D. S.; Kim, J. S. *Biochem. Biophys. Res. Commun.* **2010**, *391*, 733–738.

(13) Sugiyama, H.; Yokokawa, F.; Shioiri, T.; Katagiri, N.; Oda, O.; Ogawa, H. *Tetrahedron Lett.* **1999**, *40*, 2569–2572.

(14) Argirov, O. K.; Lin, B.; Olsen, P.; Ortwert, B. J. *Biochim. Biophys. Acta* **2003**, *1620*, 235–244.

(15) Yamada, Y.; Ishibashi, K.; Bhutto, I. A.; Tian, J.; Luty, G. A.; Handa, J. T. *Exp. Eye Res.* **2006**, *82*, 840–848.

(16) McRobert, E. A.; Tikoo, A.; Cooper, M. E.; Bach, L. A. *Int. J. Biochem. Cell Biol.* **2008**, *40*, 1570–1580.

(17) Beyer-Mears, A.; Cruz, E. *Diabetes* **1985**, *34*, 15–21.

(18) Tomlinson, D. R.; Stevens, E. J.; Diemel, L. T. *Trends Pharmacol. Sci.* **1994**, *15*, 292–298.

(19) Reddy, V. P.; Beyaz, A. *Drug Discovery Today* **2006**, *11*, 646–654.

(20) Yabe-Nishimura, C. *Pharmacol. Rev.* **1998**, *50*, 21–33.

(21) Perkins, S. J.; Johnson, L. N.; Phillips, D. C. *Carbohydr. Res.* **1977**, *59*, 19–34.

(22) Nagatani, Y.; Warashina, T.; Noro, T. *Chem. Pharm. Bull.* **2001**, *49*, 1388–1394.

(23) Schmidt, T. J.; Hildebrand, M. R.; Gunter, W. *Planta Med.* **2003**, *69*, 258–264.

(24) Wang, Y.; Liu, B. *Phytochem. Anal.* **2007**, *18*, 436–440.

(25) Satake, T.; Kamiya, K.; An, Y.; Oishi, T.; Yamamoto, J. *Biol. Pharm. Bull.* **2007**, *30*, 935–940.

(26) Wang, T.; Jiang, X.; Yang, L.; Wu, S. *J. Chromatogr. A* **2008**, *1180*, 53–58.

(27) Lim, S. S.; Jung, Y. J.; Hyun, S. K.; Lee, Y. S.; Choi, J. S. *Phytother. Res.* **2006**, *20*, 825–830.

(28) Kang, H. W.; Yu, K. W.; Jun, W. J.; Chang, I. S.; Han, S. B.; Kim, H. Y.; Cho, H. Y. *Biol. Pharm. Bull.* **2002**, *25*, 102–108.

(29) Fraisse, D.; Heitzb, A.; Carnata, A.; Carnata, A. P.; Lamaisona, J. L. *Fitoterapia* **2000**, *71*, 463–464.

(30) Lu, Y.; Sun, Y.; Foo, L. Y.; McNabb, W. C.; Molan, A. L. *Phytochemistry* **2000**, *55*, 67–75.

(31) Kerstin, H. B.; Hermann, L.; Otto, S.; Hildebert, W. *Planta Med.* **1992**, *58*, 544–548.

(32) Sawabe, A.; Nesumi, C.; Morita, M.; Matsumoto, S.; Matsubara, Y.; Komemushi, S. *J. Oleo Sci.* **2005**, *54*, 185–191.

(33) Wang, C. Z.; Yu, D. Q. *Phytochemistry* **1998**, *48*, 711–717.

(34) Lee, S.; Kim, K. S.; Jang, J. M.; Park, Y.; Kim, Y. B.; Kim, B. K. *Arch. Pharm. Res.* **2002**, *25*, 285–288.

(35) Villaseñor, I. M.; Domingo, A. P. *Teratog. Carcinog. Mutagen.* **2000**, *20*, 99–105.

(36) Kim, M. R.; Lee, S. K.; Kim, C. S.; Kim, K. S.; Moon, D. C. *Arch. Pharm. Res.* **2004**, *27*, 1029–1033.

(37) Vinson, J. A.; Howard, T. B. III. *J. Nutr. Biochem.* **1996**, *7*, 659–663.

(38) Kim, Y. S.; Jung, D. H.; Kim, N. H.; Lee, Y. M.; Kim, J. S. *Eur. J. Pharmacol.* **2007**, *562*, 12–19.

(39) Kim, Y. S.; Kim, N. H.; Lee, S. W.; Lee, Y. M.; Jang, D. S.; Kim, J. S. *Eur. J. Pharmacol.* **2007**, *569*, 171–179.

(40) Dufrane, S. P.; Malaisse, W. J.; Sener, A. *Biochem. Med.* **1984**, *32*, 99–105.